Anzeige
Mehr »
Samstag, 07.06.2025 - Börsentäglich über 12.000 News
Starke Zahlen: EBITDA bei 9 Mio.?€ - Startet jetzt die Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1JWL4 | ISIN: NO0010598683 | Ticker-Symbol: HBQ
Frankfurt
06.06.25 | 21:38
0,159 Euro
-5,36 % -0,009
1-Jahres-Chart
HOFSETH BIOCARE ASA Chart 1 Jahr
5-Tage-Chart
HOFSETH BIOCARE ASA 5-Tage-Chart
RealtimeGeldBriefZeit
0,1590,20906.06.

Aktuelle News zur HOFSETH BIOCARE Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
23.05.Hofseth Biocare ASA: Annual General Meeting completed1
16.05.Hofseth Biocare ASA: FIRST QUARTER 2025 FINANCIAL REPORT682HBC recorded total operating revenues of NOK 60.9 million in the first quarter of 2025, compared to NOK 52.4 million in the same period last year. Net operating revenues were NOK 60.7 million, reflecting...
► Artikel lesen
05.05.Hofseth Biocare ASA: NESTLÉ GARDEN OF LIFE LAUNCHES HBC OMEGO® FULL SPECTRUM OMEGAS IN THE US4
05.05.Hofseth Biocare ASA: SUCCESSFUL PLACEMENT OF NEW CHF-DENOMINATED UNSECURED BONDS2
02.05.Hofseth Biocare ASA: NOTICE OF ANNUAL GENERAL MEETING 20253
11.04.Hofseth Biocare ASA: HBC ANNUAL REPORT 20246
10.03.Hofseth Biocare ASA: CONTEMPLATING UNSECURED BOND ISSUANCE7
21.02.Hofseth Biocare ASA: HBC Accelerates In Human Health And Pet Nutrition Through A Strategic Partnership With Symrise To Build Out Berkåk, Tripling The Manufacturing Capacity Of The Group458HBC will accelerate its manufacturing scale and market reach with the construction of a second enzymatic hydrolysis plant in Berkåk, Norway. Symrise will support the financing of the project through...
► Artikel lesen
HOFSETH BIOCARE Aktie jetzt für 0€ handeln
20.02.Hofseth Biocare ASA: PRIMARY INSIDER NOTIFICATION15
20.02.Hofseth Biocare ASA / notification of major holdings2
14.02.Hofseth Biocare ASA: Fourth Quarter & Full Year 2024 Financial Report1.031HBC achieved full-year sales revenue of NOK 256.8 million, a 35% increase from 2023, with strong momentum in higher-margin B2B human nutrition. The shift towards premium products, particularly CalGo®...
► Artikel lesen
12.12.24Hofseth Biocare ASA: PRIMARY INSIDER NOTIFICATION8
09.12.24Hofseth BioCare building second hydrolysis plant to extract nutrients from Atlantic salmon2
05.12.24Hofseth Biocare ASA: Commences the project for a second hydrolysis plant in Norway to triple capacity185Hofseth BioCare ASA ("HBC" or the "Company", and together with its consolidated subsidiaries, the "Group") is pleased to announce a Board resolution to start a project to build a second hydrolysis...
► Artikel lesen
08.11.24Hofseth Biocare ASA: Third Quarter 2024 Financial Report170HBC had gross operating revenues of NOK 67.9m (49.9m) in the third quarter and NOK 200.6m (171.1m) in the first nine months. The operating loss (EBITDA) for the quarter was NOK -21.0m (-16.2m) and NOK...
► Artikel lesen
23.08.24Hofseth Biocare ASA: Second Quarter And Half Year 2024 Financial Report179HBC had gross operating revenues of NOK 80.4m (76.4m) in the second quarter and NOK 132.8m (121.2m) for the half year. Adjusted for the sale of assets in the second quarter, sales revenues were NOK...
► Artikel lesen
02.07.24Hofseth Biocare ASA: HBC discovers new drug candidate for asthma and transfers it to HBC Immunology Inc.225Ålesund, 02.07.24, Hofseth BioCare ASA ("HBC" or the "Company"), a global leader in marine lipid and peptide research, today announces the decision to transfer its eosinophil-targeting drug candidate...
► Artikel lesen
17 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1